Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters

Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19; followed by molnupiravir (another prodrug of a nucleoside analogue) and the protease inhibitor nirmatrelvir. Combination of antiviral drugs may result in improved potency and help to avoid or delay the devel...

Full description

Bibliographic Details
Main Authors: Rana Abdelnabi, Piet Maes, Steven de Jonghe, Birgit Weynand, Johan Neyts
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
COVID-19
SARS-CoV-2 VoC
GS-441524
molunpiravir
antivirals, BA.5
combination
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1072202/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1072202/full

Similar Items